628691-95-2

Basic information

• Product Name: METHYL 2-CHLORO-3-FLUORO-4-PYRIDINECARBOXYLATE
• Synonyms: Methyl 2-Chloro-3-fluoroisonicotinate;2-Chloro-3-fluoro-4-pyridinecarboxylic acid methyl ester;methyl 2-chloro-3-fluoropyridine-4-carboxylate
• CAS NO: 628691-95-2
• Molecular Formula: C7H5ClFNO2
• Molecular Weight: 189.57
• Mol File: 628691-95-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 258℃
• Flash Point: 110℃
• Appearance: /
• Density: 1.386
• Vapor Pressure: 0.0145mmHg at 25°C
• Refractive Index: 1.511
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.34±0.10(Predicted)
• CAS DataBase Reference: METHYL 2-CHLORO-3-FLUORO-4-PYRIDINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-CHLORO-3-FLUORO-4-PYRIDINECARBOXYLATE(628691-95-2)
• EPA Substance Registry System: METHYL 2-CHLORO-3-FLUORO-4-PYRIDINECARBOXYLATE(628691-95-2)

Safety Data

• Hazardous Substances Data: 628691-95-2(Hazardous Substances Data)

Usage

General Description

Methyl 2-chloro-3-fluoro-4-pyridinecarboxylate is a chemical compound with the molecular formula C7H5ClFNO2. It is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. This chemical is known for its versatile reactivity and can be used as an intermediate in the production of various drugs and pesticides. It is important to handle this chemical with caution, as it may pose health hazards if not used properly.

InChI:InChI=1/C7H5ClFNO2/c1-12-7(11)4-2-3-10-6(8)5(4)9/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 1225047-26-6 2-chloro-3-fluoropyridine-4-carbonyl chloride 
• 628691-93-0 2-chloro-3-fluoro-pyridine-4-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 876919-08-3 methyl 3-fluoropyridine-4-carboxylate 

Relevant articles and documents

Fluorinated derivatives of pyridine-2,4-dicarboxylate are potent inhibitors of human 2-oxoglutarate dependent oxygenases

2-Oxoglutarate (2OG) oxygenases have important roles in human biology and are validated medicinal chemistry targets. Improving the selectivity profile of broad-spectrum 2OG oxygenase inhibitors may help enable the identification of selective inhibitors for use in functional assignment work. We report the synthesis of F- and CF3-substituted derivatives of the broad-spectrum 2OG oxygenase inhibitor pyridine-2,4-dicarboxylate (2,4-PDCA). Their inhibition selectivity profile against selected functionally distinct human 2OG oxygenases was determined using mass spectrometry-based assays. F-substituted 2,4-PDCA derivatives efficiently inhibit the 2OG oxygenases aspartate/asparagine-β-hydroxylase (AspH) and the JmjC lysine-specific Nε-demethylase 4E (KDM4E); The F- and CF3-substituted 2,4-PDCA derivatives were all less efficient inhibitors of the tested 2OG oxygenases than 2,4-PDCA itself, except for the C5 F-substituted 2,4-PDCA derivative which inhibited AspH with a similar efficiency as 2,4-PDCA. Notably, the introduction of a F- or CF3-substituent at the C5 position of 2,4-PDCA results in a substantial increase in selectivity for AspH over KDM4E compared to 2,4-PDCA. Crystallographic studies inform on the structural basis of our observations, which exemplifies how a small change on a 2OG analogue can make a substantial difference in the potency of 2OG oxygenase inhibition.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.